Lifeward Reports Progress in Q2 Financial Results
Lifeward Ltd. (NASDAQ: LFWD), a pioneering entity in medical technology focused on innovative mobility solutions for individuals with physical disabilities, has recently unveiled its financial results for the second quarter of the fiscal year 2025.
Key Achievements and Developments
The second quarter has marked a significant period for Lifeward, showcasing a series of notable milestones that emphasize its commitment to advancing the execution of its business strategy. One of the key highlights was the achievement of FDA clearance for the ReWalk 7 Personal Exoskeleton, which was launched in the U.S. market earlier this year. The positive customer response has further solidified Lifeward's reputation in the industry.
Growing Pipeline and Qualified Leads
In addition to the product launch, Lifeward reported a remarkable increase in its U.S. pipeline, where it generated over 130 qualified leads, indicating a robust demand for its innovative solutions. The strategic partnership with CorLife has also helped streamline processes for workers' compensation claims, demonstrating Lifeward's growing influence in the healthcare ecosystem.
Financial Overview for Q2 2025
During the second quarter of 2025, Lifeward registered revenues totaling $5.7 million, a 15% decline compared to the same quarter in 2024, though it reflects a healthy 14% growth from $5.0 million in the previous quarter. Notably, revenue from traditional products, including the ReWalk Personal Exoskeleton, experienced a slight dip. However, when excluding one-time Medicare-related revenue from the previous year, product sales exhibited year-on-year growth.
Cost Management and Financial Performance
Lifeward's gross margin stood at a commendable 43.9%, up from 41.1% in the corresponding quarter of the previous year. Although there was a dip in non-GAAP adjusted gross margin, the operational efficiencies, including cost-cutting measures such as facility consolidation, played a crucial role in refining financial performance.
Operational Efficiency and Leadership Changes
The total operating expenses for the quarter reached $9.1 million, primarily driven by a non-cash goodwill impairment charge of $2.8 million related to a decline in market value. However, on a non-GAAP basis, operating expenses decreased to $6 million, showcasing improved efficiency and reduced R&D spending following the completion of major development phases.
Mark Grant, Lifeward's newly appointed President and CEO, expressed optimism about the company's strategic direction. He emphasized that the emphasis on operational efficiency and cost management, alongside the appointment of a new CFO, positions Lifeward favorably for sustainable growth and expansion in the mobility solutions market.
Future Outlook and Guidance
Looking ahead, Lifeward has reset its guidance for 2025, estimating revenues between $24 million and $26 million, alongside a non-GAAP net loss projected between $12 million and $14 million. This focus on revenue enhancement, coupled with ongoing operational adjustments, aims to stabilize the financial landscape moving into the latter half of 2025.
Frequently Asked Questions
What were Lifeward's total revenues for Q2 2025?
Total revenues for Lifeward in Q2 2025 were reported at $5.7 million.
What new products did Lifeward launch recently?
Lifeward launched the ReWalk 7 Personal Exoskeleton after achieving FDA clearance.
Who are Lifeward's key leaders?
Mark Grant is the President and CEO, and Almog Adar serves as the CFO.
How did Lifeward manage its operational costs?
Through strategic cost-cutting measures and improved efficiencies, Lifeward reduced its cash burn to $3.9 million.
What is Lifeward's revenue guidance for 2025?
Lifeward has set its revenue target for 2025 between $24 million and $26 million.
